metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus lenvatinib
	pembrolizumab plus lenvatinib
	LEAP 002, 2023 Future Oncol 2021 Feb;17(6):637-648. Lancet Oncol 2023; 24:1399-1410-. NCT03713593	RCT	mHCC - 1st line (L1)	lenvatinib in combination with pembrolizumab	Lenvatinib	first-line therapy for the treatment of advanced hepatocellular carcinoma in adult participants	395 / 399	low	inconclusive	inconclusive 16 % decrease in deaths (OS) (PE) inconclusive 13 % decrease in progression or deaths (PFS) (PE)
mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)
versus placebo
	pembrolizumab alone
	KEYNOTE-240, 2020 J. Clin. Oncol. 2020; 38:193-202 Cancer 2020 Nov 24. Liver Cancer 2021 Jun;10(3):275-284. NCT02702401	RCT	mHCC - 2nd line (L2)	pembrolizumab	placebo	previously treated patients with advanced hepatocellular carcinoma (HCC)	278 / 135	low	inconclusive	suggested 22 % decrease in deaths (OS) (PE) suggested 28 % decrease in progression or deaths (PFS) (PE)
	pembrolizumab based treatment
	KEYNOTE-394, 2022 J Clin Oncol 2023; 41:1434-1443-. NCT03062358	RCT	hepatocell cancer (HCC), mHCC - 2nd line (L2)	pembrolizumab	placebo	Asian participants with previously systemically treated advanced hepatocellular carcinoma (HCC)	300 / 153	NA	conclusif	demonstrated 21 % decrease in deaths (OS) (PE) demonstrated 26 % decrease in progression or deaths (PFS) (PE)